Iconix Pharmaceuticals Names New Head of Business Development
02 Febbraio 2006 - 2:15PM
PR Newswire (US)
Cate Sabatini Brings Significant Commercial Experience to Company
MOUNTAIN VIEW, Calif., Feb. 2 /PRNewswire/ -- Iconix
Pharmaceuticals, Inc., the leader in the expanding fields of
toxico- and chemogenomics, today named Cate Sabatini to the
position of executive vice president, Business Development. Ms
Sabatini has extensive life science experience with an academic
background in computer science and a career focus in the
bioinformatics sector. At Iconix she will drive the commercial
activities of the company as it continues to support current
partners and attract new biopharmaceutical clients for its
pioneering DrugMatrix and other products that enable early
toxicology screening of drug compounds. Ms Sabatini's background
includes positions with Incyte where she was the director of
product development and delivered the first genomic microbial
database product, PathoSeq from concept to release in three months.
Later, as vice president, Customer Relations she was responsible
for account management, scientific and technical services and
customer support. Prior to Incyte, Ms Sabatini was the manager of
Information Systems at LSI Logic and a project manager for Clinical
Systems at Syntex (Roche Group) where she helped design the
industry leading clinical trials application, Oracle Clinical and
validated clinical trials applications to ensure compliance with
GLP, GMP, GCP and FDA and EC requirements. Additionally, Ms
Sabatini founded and lead Athena Consulting, where she focused on
working with life science companies including: Genentech, Applera,
Iconix and Align Technology in the areas of strategic planning,
business development and sales and marketing. "We are delighted to
have Cate join Iconix and bring her notable commercial skills to
the company," said Jim Neal, CEO, Iconix Pharmaceuticals. "With her
background, Cate will add a depth and breadth of experience to
multiple areas including product development and business relations
to help ensure we are delivering to meet the high-performance needs
of our toxicology customers." About Iconix: Iconix Pharmaceuticals,
Inc. is pioneering the new fields of toxico- and chemogenomics, the
integration of chemistry and genomics to profile drug candidates.
Iconix's technologies enable pharmaceutical companies to increase
the odds of advancing the right compounds to the clinic, reducing
attrition rates and the costs of drug discovery. Iconix provides
reference systems and know-how to predict toxic liabilities, side
effects and mechanisms of action for drug candidates. The company
has collaborations with Bristol Myers Squibb, Abbott Laboratories,
ICOS, Schering-Plough (NYSE:SGP), AstraZeneca, Taisho
Pharmaceutical Co., Ltd., Eisai Co., Ltd. and other leading
companies. Iconix also provides research, training and support to
the U.S. Food and Drug Administration, Center for Drug Evaluation
and Research (CDER) under an agreement to advance CDER's study of
the application of genomic technologies in the regulatory approval
process. Iconix's DrugMatrix system has been installed at the FDA
for use by CDER scientists and reviewers in a diverse range of
chemogenomics applications. The company also has strategic
partnerships with leading life sciences companies including MDS
Pharma Services (TSE:MDS)(NYSE:MDZ) and GE Healthcare.
Headquartered in Mountain View, California, Iconix was founded in
1998 and is privately held. For more information, visit
http://www.iconixpharm.com/. CONTACT: Alan Engelberg of Iconix
Pharmaceuticals, +1-650-567-5527, or ; or Jennifer Larson,
+1-415-946-1074, or , for Iconix Pharmaceuticals. DATASOURCE:
Iconix Pharmaceuticals, Inc. CONTACT: Alan Engelberg of Iconix
Pharmaceuticals, +1-650-567-5527, or ; or Jennifer Larson,
+1-415-946-1074, or , for Iconix Pharmaceuticals Web site:
http://www.iconixpharm.com/
Copyright
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Mds (NYSE:MDZ)
Storico
Da Lug 2023 a Lug 2024